Crinetics Pharma Bets Big on Palsonify Launch

Crinetics Pharma ((CRNX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Crinetics Pharma’s latest earnings call struck an overall optimistic tone, with management emphasizing a strong early launch for Palsonify, rapid reimbursement gains and a deep clinical pipeline supported by a sizeable cash position. Investors were also reminded, however, of rising R&D and SG&A costs, incomplete commercial transparency and lingering reimbursement and capacity constraints that temper the otherwise positive narrative.

Early Palsonify Launch Shows Solid Commercial Traction

Palsonify delivered $10.3 million in net product revenue in the first quarter, contributing to total revenue of $10.7 million when including $0.4 million of licensing income. The company processed 232 new patient enrollment forms during the period, underscoring early demand and supporting the view that the launch is off to a stronger‑than‑typical start for a rare‑disease endocrine therapy.

Reimbursement Wins Push Coverage Toward Ambitious Targets

About 70% of patients on therapy were reimbursed by the end of the quarter and overall coverage has surpassed 60%, signaling rapid traction with payers. Management reiterated confidence in exceeding its 75% coverage goal by the end of the third quarter of 2026, a milestone seen as crucial for sustaining revenue growth and improving predictability of future cash flows.

Rising Share of Treatment‑Naive Patients Signals Earlier Use

Treatment‑naive patients increased from 5% of prescriptions in the fourth quarter of 2025 to 15% in the first quarter of 2026, tripling their share in just one quarter. This shift suggests growing physician confidence in Palsonify as a potential first‑line option rather than merely a switch therapy, a dynamic that could materially expand the addressable market over time.

Prescriber Footprint Expands Across Academic and Community Settings

Unique prescribers climbed to 263 by March 31, more than doubling from just over 125 at the end of 2023, with scripts split roughly evenly between academic centers and community practices. Across this base, Crinetics has identified roughly 1,400 patients, providing a clearer map of current opportunity and a foundation for continued penetration as awareness and access improve.

Clinical Pipeline Advances With Multiple Late‑Stage Programs

The company highlighted four major ongoing trials, including the Phase III COLMCAH study and the Phase II/III BALANCE pediatric program for atumelnant, alongside dose escalation work for candidate 9682. Multiple oral presentations and publications, including data from PATHFNDR‑1, are helping reinforce the scientific case with clinicians and payers, keeping the pipeline firmly in focus.

Efficacy Data Strengthens Palsonify’s Value Proposition

An indirect comparison from the PATHFNDR‑1 study showed placebo‑adjusted IGF‑1 normalization of 79.7% for paltusotine, more than double the outcomes reported for comparator therapies. The rapid onset of action within two to four weeks and robust symptom control are resonating with payers, aiding early formulary positioning and underpinning the company’s pricing and reimbursement arguments.

Cash War Chest Supports Long Runway and Multiple Catalysts

Crinetics ended the quarter with approximately $1.3 billion in cash, cash equivalents and investments, a balance management believes will fund operations into 2030. This sizeable war chest gives the company room to continue commercial scaling while funding multiple pivotal readouts, reducing near‑term financing risk and offering investors a degree of visibility through the rest of the decade.

Expense Guidance Maintained Despite Heavy Investment

Management reaffirmed its 2026 outlook for GAAP operating expenses of $600 million to $650 million and non‑GAAP operating expenses of $480 million to $520 million, signaling no change in spending plans despite the early stage of the launch. The company framed this consistent guidance as evidence of disciplined resource allocation, aiming to balance aggressive growth investment with predictable financial planning.

R&D Spend and SG&A Underscore Elevated Cost Structure

Research and development expense rose to $100.1 million in the first quarter from $85.1 million in the prior quarter, a roughly 17.6% increase that reflects advancing programs but also heightens attention on cash burn. Selling, general and administrative costs remained high at $50.8 million, underscoring a heavy overall expense base that could become a concern if the revenue ramp lags expectations.

Limited Visibility Into Conversion and Enrollment Dynamics

The company chose not to disclose several key metrics such as form‑to‑paid conversion rates, the revenue mix between new and rollover patients or detailed month‑over‑month enrollment trends. This lack of granularity makes it harder for investors to model the underlying demand curve and assess how sustainable early prescription and revenue growth will be.

Reimbursement Gap and Capacity Constraints Temper Uptake

Roughly 30% of patients on therapy are not yet reimbursed, and while management expects most of these to convert over time, it stopped short of providing a firm timeline. In addition, appointment availability at major treatment centers is acting as a bottleneck, with some high‑interest prescribers limited more by clinic scheduling capacity than by clinical enthusiasm for the drug.

Uncertain Timing for Key Clinical Readouts and Ex‑U.S. Ramp

Management avoided specifying timelines for pivotal data releases in areas such as carcinoid syndrome, adult AML‑related studies and the expansion of the 9682 program, even as public databases suggest some primary completion dates in 2027. The company is also progressing regulatory work in Europe, Japan and Brazil but does not anticipate meaningful international revenue in 2026, pointing instead to a more gradual, market‑by‑market rollout.

Guidance and Commercial Outlook Emphasize Long‑Term Build

The company reiterated its 2026 expense guidance while highlighting first‑quarter revenue of $10.7 million, of which $10.3 million came from product sales and $0.4 million from licensing. With cost of product revenue at $0.2 million, growing reimbursement coverage, low expected discontinuation and a cash runway into 2030, Crinetics is signaling a deliberate long‑term build rather than a rapid profit inflection.

Crinetics’ earnings call painted the picture of a company in investment mode, leveraging early success with Palsonify and a robust pipeline while willingly absorbing substantial R&D and SG&A costs. For investors, the story hinges on whether strong early launch trends, expanding coverage and a long cash runway can ultimately outweigh current opacity on conversion metrics and the near‑term drag from a heavy expense structure.